Physiological effects of slow release potassium phosphate for absorptive hypercalciuria: A randomized double-blind trial

Journal of Urology

Volumn 160, Issue 3 I, 1998, Pages 664-668

  Breslau, Neil A ^a,b   Heller, Howard J ^a   Reza Albarrán, Alfredo A ^a,c   Pak, Charles Y C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Calcium; Delayed action preparations; Phosphates; Randomized controlled trials; Urinary calculi

Indexed keywords

CALCIUM; PHOSPHATE; POTASSIUM DIHYDROGEN PHOSPHATE;

ADULT; AGED; ARTICLE; BONE TURNOVER; CALCIUM ABSORPTION; CALCIUM EXCRETION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCALCIURIA; MALE; METABOLISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLOW RELEASE FORMULATION; TABLET FORMULATION; URINARY EXCRETION; UROLITHIASIS; VITAMIN BLOOD LEVEL;

EID: 0032322405     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62749-6     Document Type: Article

References (20)

1. Pak, C. Y. C., Britton, F., Peterson, R., Ward, D., Northcutt, C., Breslau, N. A., McGuire, J., Sakhaee, K., Bush, S., Nicar, M., Norman, D. A. and Peters, P.: Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Amer. J. Med., 69: 19, 1980.
2. Insogna, K. L., Broadus, A. E., Dreyer, B. E., Ellison, A. F. and Gertner, J. M.: Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. J. Clin. Endocr. Metab., 61: 490, 1985.
3. Breslau, N. A., Preminger, G. M., Adams, B. V., Otey, J. and Pak, C. Y. C.: Use of ketoconazole to probe the pathogenetic importance of 1,25-dihydroxyvitamin D in absorptive hypercalciuria. J. Clin. Endocr. Metab., 75: 1446, 1992.
4. Van Den Berg, C. J., Kumar, R., Wilson, D. M., Heath, H., III and Smith, L. H.: Orthophosphate therapy decreases urinary calcium excretion and serum 1,25-dihydroxyvitamin D concentrations in idiopathic hypercalciuria. J. Clin. Endocr. Metab., 51: 998, 1980.
5. Insogna, K. L., Ellison, A. S., Burtis, W. J., Sartori, L., Lang, R. L. and Broadus, A. E.: Trichlormethiazide and oral phosphate therapy in patients with absorptive hypercalciuria. J. Urol., 141: 269, 1989,
6. Breslau, N. A., McGuire, J. L., Zerwekh, J. E. and Pak, C. Y. C.: The role of dietary sodium on renal excretion and intestinal absorption of calcium and on vitamin D metabolism. J. Clin. Endocr. Metab., 55: 369, 1982.
7. Lau, K., Wolf, C., Nussbaum, P., Weiner, B., DeOreo, P., Slatopolsky, E., Agus, Z. and Goldfarb, S.: Differing effects of acid versus neutral phosphate therapy of hypercalciuria. Kidney Int., 16: 736, 1979.
8. Pak, C. Y. C., Cox, J. W., Powell, E. and Bartter, F. C.: Effect of the oral administration of ammonium chloride, sodium phosphate, cellulose phosphate and parathyroid extract on the activity product of brushite in urine. Amer. J. Med., 50: 67, 1971.
9. Breslau, N. A., Padalino, P., Kok, D. J., Kim, Y. G. and Pak, C. Y. C.: Physicochemical effects of a new slow-release potassium phosphate preparation (UroPhos-K) in absorptive hypercalciuria. J. Bone Miner. Res., 10: 394, 1995.
10. Pocock, S. J. and Simon, R.: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics, 31: 103, 1975.
11. Sakhaee, K., Williams, R. H., Oh, M. S., Padalino, P., Adams-Huet, B., Whitson, P. and Pak, C. Y. C.: Alkali absorption and citrate excretion in calcium nephrolithiasis. J. Bone Miner. Res., 8: 789, 1993.
12. Ettinger, B.: Recurrent nephrolithiasis: natural history and effect of phosphate therapy. A double-blind controlled study. Amer. J. Med., 61: 200, 1976.
13. Gray, R. W., Wilz, D. R., Caldas, A. E. and Lemann, J., Jr.: The importance of phosphate in regulating plasma 1,25-(OH)2-vitamin D levels in humans: studies in healthy subjects, in calcium-stone formers and in patients with primary hyperparathyroidism. J. Clin. Endocr. Metab., 45: 299, 1977.
14. Broadus, A. E., Magee, J. S., Mallette, L. E., Horst, R. L., Lang, R., Jensen, P. S., Gertner, J. M. and Baron, R.: A detailed evaluation of oral phosphate therapy in selected patients with primary hyperparathyroidism. J. Clin. Endocr. Metab., 56: 953, 1983.
15. Portale, A. A., Halloran, B. P., Murphy, M. M. and Morris, R. C., Jr.: Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. J. Clin. Invest., 77: 7, 1986.
16. Broadus, A. E., Insogna, K. L., Lang, R., Mallette, L. E., Oren, D. A., Gertner, J. M., Kliger, A. S. and Ellison, A. F.: A consideration of the hormonal basis and phosphate leak hypothesis of absorptive hypercalciuria. J. Clin. Endocr. Metab., 58: 161, 1984.
17. Zerwekh, J. E., Sakhaee, K. and Pak, C. Y. C.: Utility and limitation of calciuric response to oral calcium load as a measure of intestinal calcium absorption: comparison with isotopic fractional calcium absorption. Invest. Urol., 19: 161, 1981.
18. Raisz, L. G. and Niemann, I.: Effect of phosphate, calcium and magnesium on bone resorption and hormonal responses in tissue culture. Endocrinology, 85: 446, 1969.
19. Yates, J., Oreffo, R. O., Mayor, K. and Mundy, G. R.: Inhibition of bone resorption by inorganic phosphate is mediated by both reduced osteoclast formation and decreased activity of mature osteoclasts. J. Bone Miner. Res., 6: 473, 1991.
20. Slatopolsky, E., Weerts, C., Lopez-Hilker, S., Norwood, K., Zink, M., Windus, D. and Delmez, J.: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. New Engl. J. Med., 315: 157, 1986.